MedPath

Oxycodone

Generic Name
Oxycodone
Brand Names
Endocet, Endodan Reformulated May 2009, Nalocet, Oxaydo, Oxy.IR, Oxycontin, Oxyneo, Percocet, Prolate, Rivacocet, Roxicet, Roxicodone, Roxybond, Targin, Targiniq, Xolox, Xtampza
Drug Type
Small Molecule
Chemical Formula
C18H21NO4
CAS Number
76-42-6
Unique Ingredient Identifier
CD35PMG570
Background

Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period. The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.

Indication

Oxycodone is indicated for the treatment of moderate to severe pain. There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.

Associated Conditions
Severe Acute Pain, Severe Pain, Severe, Chronic Pain, Acute, moderate Pain, Chronic, moderate Pain
Associated Therapies
-
Clinical Trials
Related News

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Not Applicable
Terminated
Conditions
Chronic Myeloproliferative Disorders
Brain and Central Nervous System Tumors
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Pain
Precancerous Condition
Unspecified Adult Solid Tumor, Protocol Specific
Lymphoma
Lymphoproliferative Disorder
Interventions
Drug: methadone hydrochloride
Drug: morphine sulfate
Drug: oxycodone hydrochloride
First Posted Date
2008-08-01
Last Posted Date
2020-09-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
1
Registration Number
NCT00726830
Locations
🇺🇸

Palmetto Hematology Oncology, PC at Gibbs Regional Cancer Center, Spartanburg, South Carolina, United States

🇺🇸

M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain

Phase 1
Completed
Conditions
Pain, Fracture, Sprain
Interventions
Drug: Lansoprazole
Drug: Fentanyl
Drug: Oxycodone
First Posted Date
2008-05-28
Last Posted Date
2017-02-09
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
60
Registration Number
NCT00685295
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Controlled-Release Oxycodone For Postoperative Analgesia After Video-Assisted Thoracic Surgery

Phase 4
Terminated
Conditions
Anesthesia Recovery Period
Pain, Postoperative
Interventions
Drug: Morphine
Drug: oxycodone
Procedure: Paravertebral block
Drug: Propofol
Drug: Remifentanil
Drug: Paracetamol
First Posted Date
2008-05-21
Last Posted Date
2012-01-06
Lead Sponsor
University of Parma
Target Recruit Count
22
Registration Number
NCT00681174
Locations
🇮🇹

University Hospital / Azienda Ospedaliero-Universitaria, Parma, PR, Italy

Oxycodone and Pregabalin for the Treatment of Oncological Neuropathic Pain

Phase 2
Completed
Conditions
Cancer
Pain
Interventions
Drug: oxycodone
Drug: pregabalin
First Posted Date
2008-03-18
Last Posted Date
2011-02-02
Lead Sponsor
Associazione Progetto Oncologia UMAN.A
Target Recruit Count
80
Registration Number
NCT00637975
Locations
🇮🇹

Ospedale Sacro Cuore, Negrar, Verona, Italy

🇮🇹

Ospedali Riuniti, Bergamo, Italy

🇮🇹

Ospedale S. Orsola, Brescia, Italy

and more 4 locations

A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an Infusion

Phase 3
Terminated
Conditions
Severe Caner Pain
First Posted Date
2008-02-29
Last Posted Date
2018-10-24
Lead Sponsor
Mundipharma Research Limited
Target Recruit Count
33
Registration Number
NCT00626600
Locations
🇬🇧

Royal Marsden Hospital, London, United Kingdom

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

Phase 3
Completed
Conditions
Arthralgia
Bunion
Hallux Valgus
Pain
Interventions
Drug: placebo
Drug: oxycodone
Drug: Tapentadol (CG5503)
First Posted Date
2008-02-13
Last Posted Date
2014-05-09
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
901
Registration Number
NCT00613938

A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain

Phase 2
Completed
Conditions
Cancer
Pain
Constipation
Interventions
Drug: Oxycodone/Naloxone
Drug: Oxycodone
First Posted Date
2007-08-09
Last Posted Date
2018-10-23
Lead Sponsor
Mundipharma Research GmbH & Co KG
Target Recruit Count
230
Registration Number
NCT00513656
Locations
🇬🇧

Dr S Ahmedzai, Sheffield, United Kingdom

Effects of Garlic Supplements on Opioids in Healthy Volunteers

Phase 4
Completed
Conditions
Healthy, No Evidence of Disease
Interventions
Dietary Supplement: garlic powder tablets
Drug: oxycodone
First Posted Date
2007-07-11
Last Posted Date
2017-04-07
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
15
Registration Number
NCT00499460
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.

Phase 4
Terminated
Conditions
Osteoarthritis
Interventions
Drug: placebo
Drug: celecoxib
Drug: Oxycodone
First Posted Date
2007-06-11
Last Posted Date
2021-04-14
Lead Sponsor
Pfizer
Target Recruit Count
6
Registration Number
NCT00484718
Locations
🇺🇸

VAPAHCS, Palo Alto, California, United States

🇺🇸

Stanford University, Stanford, California, United States

A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

Phase 2
Terminated
Conditions
Osteoarthritis
Interventions
Drug: Placebo
Drug: PF-000592379
Drug: Oxycodone
First Posted Date
2007-06-08
Last Posted Date
2011-04-29
Lead Sponsor
Pfizer
Target Recruit Count
113
Registration Number
NCT00483977
Locations
🇺🇸

Pfizer Investigational Site, Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy